RAPACT 10MG TABLET contains Everolimus which belongs to the group of medicines called Anticancer agents. It is used to treat hormone receptor-positive advanced breast cancer in postmenopausal women, in whom other treatments, advanced tumours called neuroendocrine tumours that originate from the stomach, bowels, lung or pancreas, advanced kidney cancer (advanced renal cell carcinoma), where other treatments (VEGF-targeted therapy) have not helped stop your disease.
Before taking RAPACT 10MG TABLET, inform your doctor if you have or ever had liver problems, diabetes, need to receive a vaccine, high cholesterol, recent major surgery or unhealed wound, an infection, hepatitis B, and are about to receive radiation therapy. RAPACT 10MG TABLET is not recommended to use in children and adolescents (under 18 years of age). Consult your doctor before taking the medicine.
RAPACT 10MG TABLET should be used with caution in elder patients (65 years and above). RAPACT 10MG TABLET is generally not recommended for use among pregnant and breastfeeding women. The most common side effects of taking RAPACT 10MG TABLET are fever, cough, difficulty breathing, wheezing, swelling, feeling of heaviness or tightness, pain. Contact your doctor for advice if any of the symptoms worsen.
It is used to treat adult patients with:
RAPACT 10MG TABLET reduces the blood supply to the tumour and slows down the growth and spread of cancer cells.
Take RAPACT 10MG TABLET as advised by your physician. Swallow the medicine with enough water. Do not crush or chew the RAPACT 10MG TABLET. The correct dose and duration will be decided by your physician for you depending on your age, body weight, and disease condition.
Stop taking RAPACT 10MG TABLET and contact your doctor immediately if you experience any of the following side effects:
Drink more fluids, such as water or fruit juice to keep yourself hydrated. Do not consume any medicine on your own without taking advice from your doctor.
Take this medicine with, or just after meals. Have simple meals. Avoid eating food that is rich in oil or spicy foods.
Try to rest and relax. Eat and drink gradually or try to have lesser and more frequent meals. Keep a heating pad on your stomach. Contact your physician if the symptom does not improve.
RAPACT 10MG TABLET is not recommended for use in pregnant women unless considered clearly necessary. Consult your doctor before taking RAPACT 10MG TABLET.
RAPACT 10MG TABLET is generally not recommended for use in breastfeeding women as it may pass through breast milk. Consult your doctor before taking RAPACT 10MG TABLET.
Do not drive or operate any machines if you feel tired (fatigue) after taking RAPACT 10MG TABLET.
RAPACT 10MG TABLET should be taken with caution in patients with kidney problems. Consult your doctor before taking RAPACT 10MG TABLET.
RAPACT 10MG TABLET should be taken with caution in patients with liver problems. Consult your doctor before taking RAPACT 10MG TABLET.
Do not take RAPACT 10MG TABLET if you are allergic to Everolimus, or any of the other ingredients of RAPACT 10MG TABLET.
RAPACT 10MG TABLET is not recommended to use in children and adolescents (under 18 years of age) Consult your doctor before taking [GBKEYWORD].
RAPACT 10MG TABLET should be used with caution in elderly patients (above 65 years of age). Consult your doctor before taking RAPACT 10MG TABLET.
Before taking RAPACT 10MG TABLET, inform your physician if you:
A. Drug-Drug interactions:
Before taking RAPACT 10MG TABLET, inform your doctor if you are taking any of the following medicine:
B. Drug-Food interactions:
Avoid having grapefruit or grapefruit juice while taking RAPACT 10MG TABLET as it may increase the risk of side effects.
Overdosage:
If you or anyone else accidentally takes too much of RAPACT 10MG TABLET, consult your doctor immediately or visit the nearby hospital.
Drug | : | Everolimus |
Pharmacological Category | : | Anti-cancer agents |
Therapeutic Indication | : | Hormone receptor-positive advanced breast cancer in postmenopausal women, advanced tumours called neuroendocrine tumours that originate from the stomach, bowels, lung or pancreas, advanced kidney cancer (advanced renal cell carcinoma) |
Dosage Forms | : | Tablet |
Q: Is there any food to avoid while taking RAPACT 10MG TABLET?
A: Avoid having grapefruit or grapefruit juice while taking RAPACT 10MG TABLET as it may increase the risk of side effects. Consult your physician for advice before taking RAPACT 10MG TABLET.
Q: Can I stop taking RAPACT 10MG TABLET if I feel my condition is improved?
A: Do not stop taking RAPACT 10MG TABLET even if you feel improved because the condition may become worsen. Consult your doctor before stopping RAPACT 10MG TABLET.
Q: How to take RAPACT 10MG TABLET?
A: Take RAPACT 10MG TABLET as advised by your physician. Swallow the medicine with enough water. Do not crush or chew the medicine. The correct dose and duration will be decided by your physician for you depending on your age, body weight, and disease condition.
Q: How do RAPACT 10MG TABLET works?
A: RAPACT 10MG TABLET reduces the blood supply to the tumour and slows down the growth and spread of cancer cells.
Q: Can I take RAPACT 10MG TABLET along with antiepileptics?
A: Antiepileptics like phenytoin, phenobarbital, or carbamazepine will affect the efficacy of RAPACT 10MG TABLET. Consult your doctor before taking RAPACT 10MG TABLET.
Q: Is it safe to use RAPACT 10MG TABLET in children?
A: RAPACT 10MG TABLET is not recommended to use in children and adolescents (under 18 years of age) Consult your doctor before taking RAPACT 10MG TABLET.
Q: RAPACT 10MG TABLET is safe for pregnant and breastfeeding women?
A: RAPACT 10MG TABLET is generally not recommended for use in pregnant and breastfeeding women unless considered clearly necessary. Consult your doctor before taking RAPACT 10MG TABLET.
1. Alan M. Krensky, Jamil R. Azzi, and David A. Hafler. Immunosuppressants and Tolerogens. Goodman & Gilman’s: The Pharmacological basics of Therapeutics. 13th Edition. New York McGraw Hill Medical 2018. Page – 638-653.
2. David N. Franz, Elena Belousova, Steven Sparagana, E. Martina Bebin, Michael D. Frost, Rachel Kuperman, et.al. Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Results from the EXIST-1 Study. Journal of Plos one. June 2018. [Accessed on 11th June 2022] https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0158476
3. Katarzyna Bobeff, Karolina Krajewska, Dobromila Baranska, Katarzyna Kotulska, Sergiusz Jozwiak, Wojciech Mlynarski and Joanna Trelinska. Maintenance Therapy With Everolimus for Subependymal Giant Cell Astrocytoma in Patients With Tuberous Sclerosis –Results From the EMINENTS Study. Journal of Frontiers in Neurology. April 2021. [Accessed on 11th June 2022] https://www.frontiersin.org/articles/10.3389/fneur.2021.581102/full
4. Peri M, Fazio N. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumor of the Lung: Patient Selection and Special Considerations. Systematic and Critical Review of the Literature. Journal of lung cancer: targets and therapy. June 2020. [Accessed on 11th June 2022] https://www.dovepress.com/clinical-evaluation-of-everolimus-in-the-treatment-of-neuroendocrine-t-peer-reviewed-fulltext-article-LCTT
5. Ajay Dhakal, Roby Antony Thomas, Ellis G Levine, Adam Brufsky, Kazuaki Takabe, Matthew G Hanna, et.al. Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. SAGE Journals (July 2020). [Accessed on 11th June 2022] https://journals.sagepub.com/doi/full/10.1177/1178223420944864
6. Novartis Pharmaceuticals UK Limited. Electronic Medicines Compendium (EMC). [Revised in January 2022] [Accessed 11th June 2022] https://www.medicines.org.uk/emc/files/pil.6658.pdf
7. Accord Healthcare Limited. Electronic Medicines Compendium (EMC). [Revised in February 2022] [Accessed 11th June 2022] https://www.medicines.org.uk/emc/files/pil.11084.pdf
8. Novartis Pharmaceuticals Corporation. US Food and Drug Administration. [Revised in July 2012] [Accessed on 11th June 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
Written By Dr. Janet.C, Pharm.D
Last updated on 23 Mar 2023 | 06:01 PM(IST)
The contents of this website are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition. Do not disregard professional medical advice or delay in seeking it because of something you have read on this website.